Study Selection:
The EndNote Reference Manager (Version X7.5; Clarivate Analytics,
Philadelphia, Pennsylvania) was used to find and eliminate duplicate
articles after transferring the articles found by the systematic search.
Two independent reviewers (MS and SO) carefully examined the titles and
abstracts of the remaining publications before thoroughly going over the
whole text to confirm relevance. Discussion was used to settle any
disagreements. Studies were chosen if they matched the predetermined
qualifying requirements listed below : (a) Covid-19 patients on
molnupiravir therapy (b) Patients above the age of 18 years (c) Patients
taking 800mg, 400mg, and 200 mg molnupiravir.(d) Clinical trials
(randomised controlled trial) Studies that included patients aged
< 18, patients with 50mg, 300mg, and 600mg of molnupiravir
were excluded since a few studies have enrolled the patient on the
aforementioned dosage of molnupiravir. Combination therapy was excluded
as well. Duplicate records, case reports, commentaries, and editorials
were also excluded.